These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 11934260)
1. Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Zhang JC; Qi X; Juarez J; Plunkett M; Donaté F; Sakthivel R; Mazar AP; McCrae KR Can J Physiol Pharmacol; 2002 Feb; 80(2):85-90. PubMed ID: 11934260 [TBL] [Abstract][Full Text] [Related]
2. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. Zhang JC; Claffey K; Sakthivel R; Darzynkiewicz Z; Shaw DE; Leal J; Wang YC; Lu FM; McCrae KR FASEB J; 2000 Dec; 14(15):2589-600. PubMed ID: 11099478 [TBL] [Abstract][Full Text] [Related]
3. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Zhang JC; Donate F; Qi X; Ziats NP; Juarez JC; Mazar AP; Pang YP; McCrae KR Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12224-9. PubMed ID: 12196635 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5. McCrae KR; Doñate F; Merkulov S; Sun D; Qi X; Shaw DE Curr Cancer Drug Targets; 2005 Nov; 5(7):519-28. PubMed ID: 16305348 [TBL] [Abstract][Full Text] [Related]
5. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Colman RW; Jameson BA; Lin Y; Johnson D; Mousa SA Blood; 2000 Jan; 95(2):543-50. PubMed ID: 10627460 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiogenesis by a monoclonal antibody to kininogen as well as by kininostatin which block proangiogenic high molecular weight kininogen. Colman RW Int Immunopharmacol; 2002 Dec; 2(13-14):1887-94. PubMed ID: 12489802 [TBL] [Abstract][Full Text] [Related]
7. Kininostatin as an antiangiogenic inhibitor: what we know and what we do not know. Guo YL; Wang S; Colman RW Int Immunopharmacol; 2002 Dec; 2(13-14):1931-40. PubMed ID: 12489806 [TBL] [Abstract][Full Text] [Related]
9. The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases. Liu Y; Sainz IM; Wu Y; Pixley R; Espinola RG; Hassan S; Khan MM; Colman RW Exp Cell Res; 2008 Feb; 314(4):774-88. PubMed ID: 18062965 [TBL] [Abstract][Full Text] [Related]
10. Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen. Wang S; Hasham MG; Isordia-Salas I; Tsygankov AY; Colman RW; Guo YL Am J Physiol Heart Circ Physiol; 2003 Jun; 284(6):H1917-23. PubMed ID: 12742823 [TBL] [Abstract][Full Text] [Related]
11. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Guo YL; Wang S; Colman RW Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1427-33. PubMed ID: 11557667 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. Colman RW; Pixley RA; Sainz IM; Song JS; Isordia-Salas I; Muhamed SN; Powell JA; Mousa SA J Thromb Haemost; 2003 Jan; 1(1):164-70. PubMed ID: 12871554 [TBL] [Abstract][Full Text] [Related]
14. Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species. Sun D; McCrae KR Blood; 2006 Jun; 107(12):4714-20. PubMed ID: 16418331 [TBL] [Abstract][Full Text] [Related]
15. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Juarez JC; Guan X; Shipulina NV; Plunkett ML; Parry GC; Shaw DE; Zhang JC; Rabbani SA; McCrae KR; Mazar AP; Morgan WT; Doñate F Cancer Res; 2002 Sep; 62(18):5344-50. PubMed ID: 12235005 [TBL] [Abstract][Full Text] [Related]
16. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. Chavakis T; Kanse SM; Pixley RA; May AE; Isordia-Salas I; Colman RW; Preissner KT FASEB J; 2001 Nov; 15(13):2365-76. PubMed ID: 11689462 [TBL] [Abstract][Full Text] [Related]
17. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Liu Y; Pixley R; Fusaro M; Godoy G; Kim E; Bromberg ME; Colman RW Oncogene; 2009 Jul; 28(30):2756-65. PubMed ID: 19483730 [TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Cao DJ; Guo YL; Colman RW Circ Res; 2004 May; 94(9):1227-34. PubMed ID: 15044324 [TBL] [Abstract][Full Text] [Related]
19. Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo. Hassan S; Sainz IM; Khan MM; Bradford HN; Isordia-Salas I; Kashem SW; Sartor RB; Colman RW Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2959-65. PubMed ID: 17293494 [TBL] [Abstract][Full Text] [Related]
20. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. Guo YL; Wang S; Cao DJ; Colman RW J Cell Biochem; 2003 Jun; 89(3):622-32. PubMed ID: 12761895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]